

Express Mail Label No. EK611905193US
Date of Deposit: June 13, 2001



PATENT APPLICATION
Attorney Docket No.: 00960-569 (CBM-69)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Charette *et al.*
ASSIGNEE : Creative Biomolecules, Inc.
SERIAL NUMBER : 09/509,648
FILING DATE : October 5, 2000
FOR : ENHANCEMENT OF MORPHOGEN ACTIVITY
EXAMINER : B. Bunner
ART UNIT : 1647

Assistant Commissioner for Patents
Washington, D.C. 20231

June 13, 2001
Boston, Massachusetts

**RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING
REQUIREMENT UNDER 37 CFR §§ 1.821 - 1.825**

Sir:

In response to the May 24, 2001 Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, Applicants file this Response in order to incorporate the Sequence Listing, filed herewith, into the U.S.S.N. 09/509,648 patent application. Applicants concurrently submit herewith a initial computer readable form (CFR) copy of the "Sequence Listing", a paper copy of the "Sequence Listing" and a statement that the content of the paper and computer readable copies are the same and include no new matter, in compliance with 37 C.F.R. §§ 1.821-1.825.

This response is due on or before June 23, 2001. Applicants believe that no fee is required for the filing of the present application. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 (Reference No. 00960-569, CBM-69).

Applicant(s): Charette et al.
U.S.S.N.: 09/509,648

Please amend the above-identified application as follows:

In the Specification:

Please insert the Sequence Listing, pages 1-10, at the end of the specification.


REMARKS

Applicants submit a Sequence Listing for the nucleotide sequence disclosed in the specification in compliance with the requirements for patent applications containing nucleotide sequences and/or amino acid sequence disclosures. 37 C.F.R. §§ 1.821-1.825. No new matter is added.

CONCLUSION

This application is believed to be in condition for allowance, and a statement to this effect is respectfully requested. Should any questions or issues arise concerning this application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Ehrli, Reg. No. 39,529
Barry J. Marenberg, Reg. No. 40,715

Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241